GlassScriptPhysician profile
Subash Nepal
NPI 1740701580
$1,013.63
in general payments reported to CMS, 2019-2025
15 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $116 · 2024: $615 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $220.28 | 2023-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $205.92 | 2024 | |
| Pfizer INC. | $161.93 | 2023-2025 | |
| Philips North America LLC | $75.82 | 2025 | Igt Devices Undivided |
| E.R. Squibb & Sons, L.L.C. | $61.32 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $55.02 | 2023-2024 | Tagrisso, Brilinta |
| Abbott Laboratories | $50.65 | 2024 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.24 | 2024 | Lifevest |
| Novo Nordisk INC | $30.84 | 2025 | Wegovy |
| Smith+Nephew, INC. | $22.12 | 2025 | Pico 7 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.80 | 2025 | Jardiance |
| Heartflow, INC. | $19.75 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $19.60 | 2023 | Austedo Xr |
| United Therapeutics Corporation | $15.80 | 2025 | Tyvaso |
| Atricure, INC. | $14.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subash Nepal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.